This study evaluated the pharmacokinetics and safety of 3 antistaphylococcal antibiotics in term and premature infants. Up to 32 infants were enrolled for each antibiotic. The study was open to children of both sexes and all racial and ethnic groups. The study lasted approximately 18 months; each infant in the study participated for up to 10 days.
In premature infants, 70% of late-onset infection in the neonatal intensive care unit is due to staphylococcal species. The majority of coagulase-negative Staphylococcus isolates (95%) and Staphylococcus aureus isolates (40%) are methicillin-resistant. Infants with these infections have lengthy hospitalizations and an increased risk of septic shock, severe necrotizing pneumonia, and neurodevelopmental impairment, as well as a high risk of mortality (up to 40%). Rifampin, clindamycin, and ticarcillin-clavulanate all have activity against staphylococcal species. However, the correct dosing and safety of these antibiotics had not been established in all infant populations.
This study determined the pharmacokinetics of rifampin, clindamycin, and ticarcillin-clavulanate in term and premature infants. We measured the levels of each antibiotic in each infant, thereby helping to determine the best dose of these drugs to treat staphylococcal infections in these patients. It is likely that the drugs behave differently in premature infants than they do in older children and adults due to the immaturity of their metabolic and kidney pathways; thus, identifying the correct dosages represents a critical public health need. We enrolled up to 32 infants for each drug. The drugs were given over 2–4 days, and the infants were monitored for another 7 days for any drug side effects.
- Rifampin Pharmacokinetics and Safety in Preterm and Term Infants Antimicrobial Agents and Chemotherapy • May 2019. Smith PB, Cotten CM, Hudak ML, Sullivan JE, Poindexter BB, Cohen-Wolkowiez M, Boakye-Agyeman F, Lewandowski A, Anand R, Benjamin DK Jr, Laughon MM; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Rifampin is active against methicillin-resistant staphylococcal species and tuberculosis (TB). We performed a multicenter, prospective pharmacokinetic (PK) and ...
- Pharmacokinetics of Clindamycin in Obese and Nonobese Children Antimicrobial Agents and Chemotherapy • March 2017. Smith MJ, Gonzalez D, Goldman JL, Yogev R, Sullivan JE, Reed MD, Anand R, Martz K, Berezny K, Benjamin DK Jr, Smith PB, Cohen-Wolkowiez M, Watt K; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Although obesity is prevalent among children in the United States, pharmacokinetic (PK) data for ...
NICHD Data and Specimen Hub (DASH):
Rifampin - PK of Antistaphylococcal Antibiotics in Infants
Matthew Laughon, MD, MPH
University of North Carolina
Chapel Hill, NC
- PTN study contributes to successful treatment of MRSA abscess in preterm infant Early this summer, Lucas,* a one-month-old infant born 9 weeks prematurely, was receiving routine respiratory support in the neonatal intensive care unit at the University of North Carolina Children’s Hospital when he suddenly developed a dangerous neck abscess. Upon testing, the infection was found to be caused by methicillin-resistant Staphylococcus aureus (MRSA) bacteria. Staphylococcus infections ...
- The PTN anti-staph trial marks its first enrollment Dr. Barry Bloom and Ms. Paula Delmore at Wesley Medical Center in Wichita, Kansas, have enrolled the first baby into the Pharmacokinetics of Anti-staphylococcal Antibiotics in Infants trial. The infant—born at 24 weeks gestation and now 52 days old—is receiving clindamycin, one of three anti-staphylococcal antibiotics routinely used in preemies to treat staphylococcal infections. Seventy percent ...